EVO

Clarity Technologies Announces Significant Enhancements and Strategic Integrations to The Clarity Practice Performance System

Retrieved on: 
목요일, 5월 9, 2024
Education, Clarity, EVO, Cataract, Software, Electronic health record, Intraocular lens, SMS, SVP, Patient, CRM, Patient satisfaction, Nursing

BOISE, Idaho, May 9, 2024 /PRNewswire/ -- Clarity Technologies, which recently revealed its rebrand following the merger of Engage Technologies Group and APX Platform, announces substantial new product features and strategic integrations for the Clarity Practice Performance System.

Key Points: 
  • BOISE, Idaho, May 9, 2024 /PRNewswire/ -- Clarity Technologies, which recently revealed its rebrand following the merger of Engage Technologies Group and APX Platform, announces substantial new product features and strategic integrations for the Clarity Practice Performance System.
  • The Clarity Practice Performance System is a first-of-its-kind healthcare practice software designed to give practice managers and owners a holistic way to optimize practice operations.
  • Finally, Clarity is announcing strategic integrations with robust EHRs like ModMed and Symplast, as well as the practice management software; Promptly.
  • Additionally, the integration with Symplast allows for seamless access to the Clarity Practice Performance System analytics module that provides structured data, industry benchmarks, and actionable insights for aesthetic practices.

STAAR Surgical Reports First Quarter 2024 Results

Retrieved on: 
화요일, 5월 7, 2024
General Health, Surgery, Medical Devices, Health, Optical, Sale, Near-sightedness, Table, IOL, Presbyopia, Investment, EVO, Research, Depreciation, STAAR, ICL, Patient, Access, Marketing, Adjustment, Fruit, Cataract, Advertising, Astigmatism, GAAP, Growth

STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.

Key Points: 
  • STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.
  • Gross profit margin for the first quarter of 2024 was 78.9% of net sales compared to the prior year quarter of 78.3% of net sales.
  • Product and country mix favorably impacted gross margin in the first quarter of 2024 as compared to the prior year quarter.
  • Operating expenses for the first quarter of 2024 were $63.3 million compared to the prior year quarter of $54.8 million.

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

Retrieved on: 
화요일, 5월 7, 2024
Optical, Health, Surgery, Medical Devices, Education, Near-sightedness, Left, Presbyopia, EVO, Refractive surgery, Cataract, PIB, STAAR, Surgeon, Nave, MD, Quality, ICL, Contact, Chairperson, Lens, ASCRS, Eye, Society, Athlete, Multimedia, Marketing, SMILE, Astigmatism, Growth, Telescopic sight

View the full release here: https://www.businesswire.com/news/home/20240507036972/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507036972/en/
    Tom Frinzi, Chair of the Board, President and CEO, STAAR Surgical (Left) and Dr. Robert T. Lin, founder and surgeon, IQ Laser Vision (Right).
  • (Photo: Business Wire)
    IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering.
  • IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months.
  • Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far.

Modern Vision Centers: Redefining the Patient Eye Care Experience Through a Fusion of Expertise, Technology, and Personalized Solutions

Retrieved on: 
화요일, 5월 7, 2024
MVC, Telehealth, EVO, Education, Heart, MD, Contact, Physician, Medicine, Vision, Growth, LASIK, Pharmaceutical industry

Personalized, modern, and convenient care is at the heart of Modern Vision Centers' approach.

Key Points: 
  • Personalized, modern, and convenient care is at the heart of Modern Vision Centers' approach.
  • MVC unites three premier Omaha practices—Kugler Vision, Modern Vision Solutions, and ilumin—into one convenient, integrated network.
  • "This model and the practices within it will set the bar for what the primary eye care experience should be.
  • Modern Vision Centers represents a truly transformative approach to eye care, combining expertise, technology, and patient education to set a new standard of excellence in the field.

EQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

Retrieved on: 
금요일, 5월 3, 2024
Annual general meeting, MDAX, Medication, EVO, Chemistry, Supervisory board, Interim, Management

The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024.

Key Points: 
  • The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024.
  • Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of experience in various management positions, most recently as CEO of Mediq and at Linde Healthcare.
  • Prof. Dr Iris Löw-Friedrich, Chairperson of Evotec’s Supervisory Board, stated: “Dr Wojczewski is the ideal candidate to become the next CEO of Evotec.
  • I have full confidence in his ability to lead Evotec and its smart people into a bright future.”

EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments

Retrieved on: 
금요일, 5월 3, 2024
Mortality, MDAX, Nephrology, Probability, EVO, Partnership, Fibrosis, Frankfurt Stock Exchange, Science, Liver, CSO, Drug development, Drug discovery, Disease, Pharmaceutical industry

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
  • The strategic partnership leverages Variant Bio’s cutting-edge genomic discovery capabilities and VB-Inference platform as well as Evotec’s extensive expertise in antifibrotic drug discovery.
  • This strategic framework allows Variant Bio to offset the early costs of drug development in exchange for a portion of the future upside.
  • Dr Matthias Evers, Chief Business Officer of Evotec, said: “We are excited to enter this collaboration with Variant Bio.

EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024

Retrieved on: 
금요일, 5월 3, 2024
MDAX, Frankfurt Stock Exchange, EDT, Webcast, EVO, BST, PIN, Broadcasting

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.
  • The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.
  • Time: 3.00 pm CEST (02.00 pm BST, 09.00 am EDT)
    To join the audio webcast and to access the presentation slides, please register via this link .
  • You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer

Retrieved on: 
금요일, 5월 3, 2024
MDAX, EVO, Human resources, CPO, Culture, Frankfurt Stock Exchange, Management

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer (“CPO”), effective 15 June 2024.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer (“CPO”), effective 15 June 2024.
  • Prior to joining Evotec, Aurélie served as the Chief Human Resources Officer (“CHRO”) at Corbion N.V., a global bio-based ingredients company headquartered in Amsterdam, Netherlands.
  • Dr Mario Polywka, Chief Executive Officer of Evotec, said: “We are delighted to welcome Aurélie to the Evotec team.
  • Aurélie Dalbiez, Evotec’s designated Chief People Officer, added: “I am very humbled to have been chosen as Evotec’s Chief People Officer.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on: 
수요일, 5월 1, 2024
Optical, Health, Surgery, Medical Devices, Corporation, Science, Medtech, Near-sightedness, Law, University, Presbyopia, American Tower, Believer, EVO, General counsel, OTC, Marketing, Commerce, Johnson & Johnson, STAAR, Surgeon, University School, Business, Partner (business rank), CareFusion, Contact, Duke University, NuVasive, Senior, Patient, Multimedia, Global marketing, Emory University, Associate, Astigmatism, Economics, Nate, Growth, Engineering, Management

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
    “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
  • “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
  • “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

STAAR Surgical to Report First Quarter Results on May 7, 2024

Retrieved on: 
월요일, 4월 29, 2024
Optical, Health, Surgery, Medical Devices, Near-sightedness, STAAR, Presbyopia, Astigmatism, Webcast, EVO

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
  • STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .